Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Sold by Deutsche Bank AG

Deutsche Bank AG decreased its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 49.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,449,835 shares of the company's stock after selling 2,393,857 shares during the quarter. Deutsche Bank AG owned about 1.95% of Organogenesis worth $7,839,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ORGO. Assenagon Asset Management S.A. raised its position in Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock valued at $9,443,000 after purchasing an additional 1,035,120 shares during the last quarter. Norges Bank purchased a new stake in Organogenesis in the 4th quarter valued at $1,543,000. Dimensional Fund Advisors LP raised its position in Organogenesis by 18.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock valued at $8,925,000 after purchasing an additional 442,772 shares during the last quarter. Renaissance Technologies LLC raised its position in Organogenesis by 31.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company's stock valued at $3,435,000 after purchasing an additional 255,600 shares during the last quarter. Finally, Prudential Financial Inc. raised its position in Organogenesis by 92.9% in the 4th quarter. Prudential Financial Inc. now owns 237,720 shares of the company's stock valued at $761,000 after purchasing an additional 114,500 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.

Analysts Set New Price Targets

Separately, Morgan Stanley boosted their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th.

Insider Transactions at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the transaction, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. This represents a 13.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 36.90% of the company's stock.

Organogenesis Stock Performance

ORGO traded down $0.07 during trading on Friday, hitting $2.90. The stock had a trading volume of 609,283 shares, compared to its average volume of 1,172,545. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm has a market capitalization of $367.88 million, a P/E ratio of -48.33 and a beta of 1.85. The company's 50-day moving average price is $4.21 and its 200 day moving average price is $3.91. Organogenesis Holdings Inc. has a twelve month low of $2.28 and a twelve month high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.17). The firm had revenue of $86.69 million during the quarter, compared to analyst estimates of $90.77 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. On average, equities research analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.